The discovery of immune checkpoints and the development of drugs represented by programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) monoclonal antibodies are landmark events in cancer immunotherapy (20–24). This evidence concerns the gene CD274 and cancer.